These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 32078355)

  • 41. Trauma treatment for veterans in buprenorphine maintenance treatment for opioid use disorder.
    Meshberg-Cohen S; Black AC; DeViva JC; Petrakis IL; Rosen MI
    Addict Behav; 2019 Feb; 89():29-34. PubMed ID: 30243036
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The case for a medication first approach to the treatment of opioid use disorder.
    Winograd RP; Presnall N; Stringfellow E; Wood C; Horn P; Duello A; Green L; Rudder T
    Am J Drug Alcohol Abuse; 2019; 45(4):333-340. PubMed ID: 31084515
    [No Abstract]   [Full Text] [Related]  

  • 43. Buprenorphine treatment retention and comorbidities among patients with opioid use disorder in a primary care setting.
    Sweeney MM; Prichett L; Fingerhood MI; Antoine D; Umbricht A; Dunn KE; Buresh ME
    Am J Addict; 2022 May; 31(3):256-260. PubMed ID: 35385169
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Creation of an algorithm for clinical decision support for treatment of opioid use disorder with buprenorphine in primary care.
    Dela Cruz AM; Walker R; Pipes R; Wakhlu S; Trivedi MH
    Addict Sci Clin Pract; 2021 Feb; 16(1):12. PubMed ID: 33608060
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Mobile Telemedicine for Buprenorphine Treatment in Rural Populations With Opioid Use Disorder.
    Weintraub E; Seneviratne C; Anane J; Coble K; Magidson J; Kattakuzhy S; Greenblatt A; Welsh C; Pappas A; Ross TL; Belcher AM
    JAMA Netw Open; 2021 Aug; 4(8):e2118487. PubMed ID: 34448869
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Impact of a pharmacist-led substance use disorder transitions of care clinic on postdischarge medication treatment retention.
    Smith A; Hansen J; Colvard M
    J Subst Abuse Treat; 2021 Nov; 130():108440. PubMed ID: 34118708
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Integrating buprenorphine maintenance therapy into federally qualified health centers: real-world substance abuse treatment outcomes.
    Haddad MS; Zelenev A; Altice FL
    Drug Alcohol Depend; 2013 Jul; 131(1-2):127-35. PubMed ID: 23332439
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A Comparison of Medication for Opioid Use Disorder Treatment Strategies for Persons Who Inject Drugs With Invasive Bacterial and Fungal Infections.
    Marks LR; Munigala S; Warren DK; Liss DB; Liang SY; Schwarz ES; Durkin MJ
    J Infect Dis; 2020 Sep; 222(Suppl 5):S513-S520. PubMed ID: 32877547
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Comparing perspectives on medication treatment for opioid use disorder between national samples of primary care trainee physicians and attending physicians.
    Kennedy-Hendricks A; Barry CL; Stone E; Bachhuber MA; McGinty EE
    Drug Alcohol Depend; 2020 Nov; 216():108217. PubMed ID: 32810837
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Prior National Drug Abuse Treatment Clinical Trials Network (CTN) opioid use disorder trials as background and rationale for NIDA CTN-0100 "optimizing retention, duration and discontinuation strategies for opioid use disorder pharmacotherapy (RDD)".
    Shulman M; Weiss R; Rotrosen J; Novo P; Costello E; Nunes EV
    Addict Sci Clin Pract; 2021 Mar; 16(1):15. PubMed ID: 33676577
    [TBL] [Abstract][Full Text] [Related]  

  • 51. County-level access to opioid use disorder medications in medicare Part D (2010-2015).
    Abraham AJ; Adams GB; Bradford AC; Bradford WD
    Health Serv Res; 2019 Apr; 54(2):390-398. PubMed ID: 30665272
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Three-month outcomes from a patient-centered program to treat opioid use disorder in Iowa, USA.
    Lynch AC; Weber AN; Hedden S; Sabbagh S; Arndt S; Acion L
    Subst Abuse Treat Prev Policy; 2021 Jan; 16(1):8. PubMed ID: 33435993
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Documented opioid use disorder and its treatment in primary care patients across six U.S. health systems.
    Boudreau DM; Lapham G; Johnson EA; Bobb JF; Matthews AG; McCormack J; Liu D; Campbell CI; Rossom RC; Binswanger IA; Yarborough BJ; Arnsten JH; Cunningham CO; Glass JE; Murphy MT; Zare M; Hechter RC; Ahmedani B; Braciszewski JM; Horigian VE; Szapocznik J; Samet JH; Saxon AJ; Schwartz RP; Bradley KA
    J Subst Abuse Treat; 2020 Mar; 112S():41-48. PubMed ID: 32220410
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Trends in Receipt of Buprenorphine and Naltrexone for Opioid Use Disorder Among Adolescents and Young Adults, 2001-2014.
    Hadland SE; Wharam JF; Schuster MA; Zhang F; Samet JH; Larochelle MR
    JAMA Pediatr; 2017 Aug; 171(8):747-755. PubMed ID: 28628701
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Office-Based Buprenorphine Treatment: Identifying Factors That Promote Retention in Opioid-Dependent Patients.
    Noe SR; Keller T
    J Addict Nurs; 2020; 31(1):23-29. PubMed ID: 32132421
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Identification and Management of Opioid Use Disorder in Primary Care: an Update.
    Donroe JH; Bhatraju EP; Tsui JI; Edelman EJ
    Curr Psychiatry Rep; 2020 Apr; 22(5):23. PubMed ID: 32285215
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A comparison of adherence, outcomes, and costs among opioid use disorder Medicaid patients treated with buprenorphine and methadone: A view from the payer perspective.
    Kinsky S; Houck PR; Mayes K; Loveland D; Daley D; Schuster JM
    J Subst Abuse Treat; 2019 Sep; 104():15-21. PubMed ID: 31370980
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The Pregnancy Recovery Center: A women-centered treatment program for pregnant and postpartum women with opioid use disorder.
    Krans EE; Bobby S; England M; Gedekoh RH; Chang JC; Maguire B; Genday P; English DH
    Addict Behav; 2018 Nov; 86():124-129. PubMed ID: 29884421
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Evaluation of an emergency department buprenorphine induction and medication-assisted treatment referral program.
    Kaucher KA; Caruso EH; Sungar G; Gawenus L; Hurlbut K; Sanchez DC; Broderick K
    Am J Emerg Med; 2020 Feb; 38(2):300-304. PubMed ID: 31387811
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Real-world changes in US health system hospital-based services following treatment with a prescription digital therapeutic for opioid use disorder.
    Velez FF; Colman S; Kauffman L; Anastassopoulos K; Murphy S; Maricich Y
    Hosp Pract (1995); 2021 Dec; 49(5):341-347. PubMed ID: 34275401
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.